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Abstract
In this article health economic implications of screening are analysed.
First, requirements screening programmes should fulfil are derived,
and methodical standards of health economic evaluation are outlined.
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1
1 Institute for Epidemiology,
Social Medicine, and Health
Using the example of newborn hearing screening, it is then examined
if empirical studies meet the methodical requirements of health eco- System Research, Hannover
nomic evaluation. Some deficits are realised: Health economic studies Medical School, Hannover,
Germany of newborn hearing screening are not randomised, most studies are
evennotcontrolled.Therefore,moststudiesdonotpresentincremental,
but only average cost-effectivenessratios(i.e. cost per case identified).
Furthermore, evidence on long-term outcomes of screening and early
interventionsisinsufficient.Inconclusion,thereisaneedforcontrolled
trials to examine differences in identified cases, but particularly to
examine long-term effects.
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1 Introduction
Screening is among the central topics of prevention in
Germany. The rationalefor screeningis to detecta target
diseaseinanearly–pre-symptomatic–phaseofdisease
and to realise better treatment outcomes by early inter-
vention compared to usual care in a later – symptomatic
– phase.
ScreeningisasubstantialpartofSHI-authorisedmedical
care (i.e. medical care for persons insured by the Social
Health Insurance SHI) for nearly 40 years. Screening in-
cludes routine well child visits (including screening for
metabolic diseases) – so-calledU1 to U11. Furthermore,
screening programmes for cancer (e.g., breast cancer,
colon cancer, and skin cancer), cardiovascular diseases,
diabetes,andrenaldiseases(“check-up35”)areoffered
to adults (each screening from a specific age of the in-
suredperson).Also,currentlyanationwidemammography
screening is established in Germany. And introduction of
further screening programmes is expected, particularly
as genetic disposition for various cancers is already or
will in future be identifiable.
Screening programmes (like all health care services) not
only have to prove medical effectiveness, but also eco-
nomic cost-effectiveness. Over the last 20 years, de-
cisions in the health care sector increasingly focus on
health economic goals. Due to demographic ageing and
technological progress the provision of health care ser-
vices is characterised by an increasing shortage of re-
sources. To limit rising health care expenses, regulatory
interventions are increasingly executed.
The proof of cost-effectiveness is based on health eco-
nomic evaluation studies. Health economic evaluation is
to assist rational decisions in health politics. Economic
evaluationprovidesinformationoncosts,outcomes,and
efficiency of medical technologies (in particular: screen-
ing) and supports decisions whether new technologies
(in particular: screening programmes) should or should
not be adopted in the health care system.
Inthisarticlescreeningisanalysedfromahealtheconom-
ic perspective. Section 2 describes the characteristics of
screening. Section 3 presents the theoretical basis of
healtheconomicevaluation.Insection4specificrequire-
ments for health economic analysis of screening pro-
grammes are discussed using the example of newborn
hearing screening. The article ends with conclusions in
section 5.
2 Screening
2.1 Definition of screening
Screening is a systematic procedure to detect a target
diseaseinanearly–pre-symptomatic–phaseofdisease.
The aim of screening is to reduce disease specific mor-
bidityandmortalitybyutilisingappropriateearlyinterven-
tions [1]. Additional benefits of an earlier intervention
compared to usual treatment in a later – symptomatic –
phase are required to justify screening tests, otherwise
unnecessary costs, unnecessary psychological strain,
and unnecessary risks would be induced [2]. Benefits of
anearlytreatmentcouldevenbe,forexample,thataless
aggressive treatmentis sufficient or the diseaseprocess
is shorter and less serious. The following screening ap-
proaches are distinguished.
• mass screening versus selective screening
• organisedscreeningversusopportunistic(orspontan-
eous) screening.
Mass screening involves the total population or at least
defined large parts of the population (e.g., all children or
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with specific risks – so-called high-risk groups – (e.g.,
women with BRCA gene mutations bearing an increased
risk for breast cancer). The frontier between mass
screening and selective screening is not unambiguous
as for many diseases differences in incidence and
prevalence are only explained by age. Only in some dis-
easeshigh-riskgroupscanbedefinedbyotherdetermin-
ants (an example is newborn hearing screening – see
section 4).
The distinction between organised screening and oppor-
tunistic screening is more obvious. Organised screening
isinitiatedbythehealthcaresystem,i.e.subpopulations
will be called on by health care providers (e.g., for
screeningattheworkplace)orwillbeinvitedforscreening
by mail, telephone or public campaigns (e.g., mammo-
graphy). In contrast, opportunistic screening is part of
routine care. It is performed when a patient is consulting
the health care system (i.e. opportunistic screening is
initiated by the patient). Examples for opportunistic
screening are blood pressure measurement and blood
glucose measurement [1].
Screening programmes are based on two (implicit) as-
sumptions: (1) early identification of risk factors can
preventtheonsetofadisease(e.g.,endoscopicidentific-
ation and excision of polyps in the colon) or (2) early de-
tection and treatment of a disease provide improved
health outcomes (concerning life expectancy and quality
of life) (e.g., mammography to detect breast cancer).
2.2 Effectiveness criteria of screening
programmes
The Word Health Organisation has presented a checklist
to assess the effectiveness of a screening programme
[3]
• the target disease should be a substantial health
problem
• the disease should be diagnosable in a latent or pre-
symptomatic phase
• thenaturalcourseofdisease–includingthetransition
from a latent to a manifest phase – should be under-
stood
• a simple, safe and sufficiently precise screening test
should exist to detect the target disease
• the screening test should be accepted in the target
population
• an effective treatment should be available. Treatment
outcomes should be the better the earlier the disease
is detected
• it shouldbe agreedon which persons must be treated
(and which treatment is adequate)
• anadequateinfrastructureforscreening,diagnostics,
and treatment should exist
• costs of a screening programme (including test, diag-
nosis and treatment) should be in a proper relation to
total costs of a disease
• screening for a disease should be a continuous pro-
cess (incidence screening) instead of a singular event
(prevalence screening).
2.3 Statistical properties of a screening
test
Screening tests should reliably discriminate between
diseased and healthy persons [1]. The validity of a
screening test depends on test sensitivity (probability of
testing positive if a person is actually diseased), test
specificity (probability of testing negative if a person is
actually healthy), and prevalence of a target disease.
As most persons of a target population are healthy low
specificity produces a large number of false-positive test
results–i.e.thepositivepredictivevalue(probabilitythat
a person is actually diseased if the test result is positive)
is low. The negative effects of false-positive test results
are additional costs of diagnostic assessment, health
risks of additional diagnostics, and the psychological
strain induced by positive test results.
The prevalence of a target disease is often more import-
ant for costs and outcome of a screening programme
than the test validity. Mass screening programmes are
not suitable for early detection of rare diseases (with low
prevalence) [2]. However, the prevalence of most dis-
eases can be adjusted by defining age limits. Mammo-
graphy, for example, is not offered to women under the
age of 50 due to low prevalence. If prevalence is not ad-
justable, an extremely high specificity should be aimed
at.
Sensitivity and specificity can be defined as a functionof
a diagnostic cut-off value (to dsicriminate between dis-
eased and healthy persons) [1], i.e. a varied cut-off point
is affecting sensitivity and specificity. In general, an in-
creaseinsensitivityimpliesadecreaseinspecificity,and
vice versa. Thus, when the cut-off point is defined the
relative importance of sensitivity and specificity should
be considered (i.e. false-positive and false-negative test
results should be traded off) [1].
2.4 Systematic errors
Evaluations of screening programmes should pay atten-
tion to systematic errors. For screening tests lead time
bias and length time bias are particularly relevant [1].
Leadtimebias:Diagnosisofatargetdiseaseisadvanced
by screening. Lead time denotes the interval between
detection of pre-symptomatic cases at screening and
usual detection of cases when clinical symptoms have
been developed. Thus, the interval between diagnosis
and death is prolonged by screening even if no gain in
lifetime is realised (so-called unadjusted period of time).
To isolate the effect of screening on survival – i.e. poten-
tial increase in life expectancy – the total interval in
screened persons between diagnosis and death has to
be adjusted for leadtime (which is a non-trivialproblem).
Length time bias: Cases of a target disease progressing
more rapidly from preclinical to clinical disease will gain
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less rapidly (i.e. the preclinical phase of disease is short-
er). These cases are less likely to be detected by screen-
ing than cases with a longer preclinical phase. Further-
more, it is often assumed that less rapidly progressing
cases have a better prognosis (particularly assumed for
cancer). Thus, cases detected by screening could have
abettersurvivalonly(oratleasttosomeextent)because
caseswithbetterprognosisaremorelikelytobedetected
at screening (length time bias).
Astheeffectsofleadtimebiasandlengthtimebias(and
possible more biases) on the outcome are extremely
complex, the utility of screening programmes should be
proofed by randomised controlled trials (RCTs).
2.5 Parameters for the determination
of screening effectiveness
Evaluation studies of screening programmes are often
based on the following outcome parameters
• number of detected cases of illness (in the screened
population (intervention group) versus in the not-
screened population (control group) )
• distributionof(cancer)stagesintheinterventiongroup
versus in the control group
• survival time of the screened versus not-screened
population
• disease-specific mortality.
If the evaluation is not based on RCTs, the first three
outcomes are no appropriate parameters for proofing
cost-effectiveness due to lead time and length time
biases. Disease-specific mortalityis thoughtto be a valid
outcome parameter. Furthermore, reduction of disease-
specific mortality is the central goal of many screening
programmes (particularly in cancer screening).
3 Health economic evaluation
3.1 Aims of health economic analysis
Economic aims are increasingly important to the health
care sector as resources are increasingly scarce due to
demographicageingandtechnologicalprogressinhealth
care.Accordingtoeconomicprinciplesprovisionofhealth
care services should be efficient which means that
1. only effective health care services will be provided
(effectiveness)
2. health care services will be produced at the lowest
possible costs (production efficiency)
3. amount, quality and structure of health care services
are based on need and/or utility of the insured popu-
lation (allocation efficiency).
Healtheconomicevaluationistoassistrationaldecisions
in health politics. Economic evaluation provides informa-
tion on costs, outcomes, and efficiency of medical tech-
nologies and supports decisions whether new technolo-
gies should or should not be adopted in the health care
system.
3.2 Approaches of health economic
evaluation
In health economic evaluation costs, effects (outcomes)
andcost-effectiveness–i.e.theratioofeffectsandcosts
– of alternative interventions are compared. The basic
approaches of health economic evaluation are [4], [5],
[6], [7] (1) cost-minimisation analysis, (2) cost-effective-
ness analysis, (3) cot-utility analysis, and (4) cost-benefit
analysis.Theevaluationapproachesdifferintheoutcome
dimension. Outcomes can be differentiated into [7], [8]
• clinical parameters
• health care outcomes
• health outcomes
• life expectancy
• quality of life (QoL)
• monetised outcomes (willingness to pay).
In cost-minimisation analyses (CMA) only costs of the
intervention alternatives are considered. It is assumed
that the relevant health outcomes are identical in the
intervention alternatives. Identical effectiveness should
be proven in clinical studies.
In cost-effectiveness analysis (CEA) outcomes are meas-
ured in real units. Possible outcomes of CEAs are clinical
parameterslikebloodpressureorlungfunctioncapacity,
healthcareoutcomeslikescreenedpersonsanddetected
cases of illness, and (intermediate or final) health out-
comes like prevented myocardial infarctions, prevented
fatalitiesorlifeyearsgained.CEAsareparticularlyappro-
priate when a dominant effect parameter is identified.
The importance of an effect parameter should be ap-
praised from the patients’ perspective. Final outcomes
tend to be particularly relevant. Clinical outcomes will be
importantwhen–basedonepidemiologicalstudies–an
extrapolation is possible from clinical to final outcomes.
Decision models will be constructed for the analysis of
long-term final outcomes. Finally, in CEAs cost and out-
come differences between intervention alternatives will
be integrated to cost-effectiveness ratios.
Incost-utilityanalyses(CUA)multipleoutcomeparameters
areconsidered.Outcomesaretransferredintoutilityunits
(usingavaluationalgorithm),andintegratedintoaunique
utility parameter. In general, global outcome parameters
life years gained and quality of life during the remaining
lifetime are integrated into an index, the so-calledquality
adjusted life years (QALYs). A QALY denotes numerically
an additional year in complete health. CUAs support
comparisons across different indications – in particular
comparisons of life prolonging interventions with mere
QoL improving interventions (e.g., a back school pro-
gramme and a bypass operation).
In cost-benefit analyses outcomes are calculated in
monetised units (similar to cost parameters). Thus mul-
tiple outcomes are considered (like in CUAs) and
moreover, costs and benefits are directly comparable. A
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providing–atleastintheory–auniquedecisioncriterion:
if benefits exceed costs (i.e. positive net benefit) the
adoptionoftheinnovativeinterventionisrecommended.
If costs exceed benefits (i.e. negative net benefits) adop-
tion of the innovative intervention is rejected. Moreover,
CBA allows comparisonsof investmentsin healthandfor
example investments in education or environment.
Mosthealtheconomicanalysesofscreeningprogrammes
arecost-effectivenessanalyses(costsperdetectedcase).
In long-term analyses also cost-utility analyses (particu-
larly for cancer screening programmes) and (restricted)
cost-benefit analyses are applied. In CBAs costs of the
screening programme are compared to savings in direct
and/or indirect costs (due to screening programme) and
(monetised) benefits. Thus, screening programmes are
efficient if
• net savings are realised (i.e. discounted savings in
direct/indirect follow-up costs overcompensate pro-
gramme costs) and health outcomes do not worsen
(restricted CBA)
• health outcomes like life years or QALYs are gained at
relative lower costs (CEA and CUA).
3.3 Incremental analysis
In health economic analysis a comparison of treatment
alternatives is performed. The comparison is based on
thefundamentalconceptofincrementalanalysis.Accord-
ing to the incremental concept, cost and outcome (e.g.,
health effect or quality-adjusted life year) differences
between two or more alternatives are derived (i.e. incre-
mental costs and outcomes). Incremental costs and in-
cremental effects or quality-adjusted life years form the
core result of a health economic evaluation, the incre-
mental cost-effectiveness ratio (see Table 1).
According to guidelines for health economic analysis, it
is crucial to select appropriate comparators. Relevant
comparators are (1) the dominant intervention (or an
intervention mix based on market share weights), (2) the
most cost-effective alternative and (3) the cost-minimal
or do-nothing alternative (if relevant) [5], [6].
3.4Perspectivesofthehealtheconomic
analysis
Health economic evaluation can be performed from dif-
ferent perspectives, e.g., the societal perspective, the
payers’ perspective or the providers’ perspective. The
differentperspectivesmustclearlybedistinguished.They
determinehowcostsandhealtheffectsofthealternatives
are defined, measured and valuated.
The societal perspective is the broadest perspective. All
costs are included, regardless of who will incur them:
healthinsurance,publicsectors(e.g.,educationinspecial
schools for hearing-impaired children), the patients and
their families (e.g., time and travel expenses), or the rest
of the society (e.g., production losses). International
guidelines recommend to use a societal perspective in
all health economic evaluations [5], [8], [9], [10].
In addition, other perspectives can be used, e.g. the
payers’ perspective [11], the providers’ perspective or
the patients’ perspective. Health technologies should
also be evaluated from the decision-maker’s viewpoint
to check whether the decision maker’s appraisal is or is
not consistent with the societal appraisal.
3.5 Costs
Cost estimation is based on a four-step process:
1. identification of the relevant cost items
2. measuring resource use
3. valuation of resource units
4. calculatingtotalcostsoftheinterventionalternatives.
Costs are defined as valuated resource consumption.
Resourceuseismeasuredinquantityunits,andvaluation
isbasedonopportunitycosts(seebelow).Fromasocietal
perspective, costs in health economic evaluations are
commonly classified into [5], [12] (see Table 2):
• direct medical costs
• direct non-medical costs
• indirect costs.
Direct costs refer to the resource consumption in the
provision of health care interventions. They encompass
the entire current resource use (e.g., the costs of a
mammography screening programme) as well as future
resource use attributable to the programme (e.g., valida-
tion of test results and diagnostics, costs or cost savings
associated with breast cancer or prevented breast can-
cer).Futurecostscanspanalifetimeinsomeindications.
Direct costs are differentiated into direct medical and
direct non-medical costs. Direct medical costs refer to
theresourceconsumptioninthehealthcaresectorasso-
ciated with the production of health interventions. Re-
source consumption includes, for example, the costs of
hospital stays, outpatient visits, pharmaceuticals and
devices. Direct non-medical costs refer to resources
supporting the medical production in the health care
sector. These are, for example, transportation costs to
medical interventions, child care costs for an ill parent,
time of patientsin the co-productionof medicalinterven-
tions, and time of family members (or volunteers) in in-
formal care for ill or disabled patients.
For the quantification of resource use a range of costing
approaches exists with micro-costing and gross-costing
defining the ends of the range [1], [3], [4], [6], [12], [13].
In gross-costing, composite intermediate products and
services (e.g. inpatient days) will be identified and
measured. Micro-costing, on the other hand, starts with
a detailed identification and measurement of services
(e.g. a hospital stay will be split into components like
consultation,operation,medication,diagnostics,nursing,
housing, food, cleaning, overheads etc) and determines
the required resource use (personnel, material, equip-
ment, building, overhead etc.).
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Table 2: Items of resource use and health economic evaluations
The valuation of health care interventions should be
based on opportunity costs. Opportunity costs refer to
the benefit of resources from the next best alternative
use. As is shown in micro-economic theory, opportunity
costs are reflected in the market prices of a perfectly
competitivemarket.Fromasocietalperspectivevaluation
based on micro-costing is preferred as most health care
resourcesarenegotiatedoncompetitivemarkets(though
an efficient resource use is not guaranteed). Prices for
healthcareservicesareoftenregulatedbypublicinstitu-
tions (e.g, Uniform Value Scale for outpatient services
and DRGs for inpatient services) or negotiated between
associations of providers and payers (e.g. outpatient
budgets). Nevertheless, these prices can be used as an
approximation of opportunity costs – with some well-
founded adjustments where required [14].
Indirect costs denote the production losses due to
• unfitness for work (in the case of illness)
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long-term illness or disability)
• premature death.
For the valuation of productivity costs, there are two
fundamental methods, the human capital approach and
the friction cost approach. The human capital approach
(HCA) suggests, that health care interventions are a kind
of investment in an individual’s human capital (similar
to, for example, education). HCA rests on neoclassical
theoryofthefirm.Accordingtoneoclassicaltheory,profit-
maximisingfirmsexpandtheirlabourinputuntilmarginal
revenueproductoflabourequalsunitlabourcosts(gross
wage plus payroll related costs) – assuming diminishing
marginal productivity of labour. Thus, according to the
human capital approach (HCA), valuation of production
losses is based on labour costs. All future productivity
losses (up to retirement age) will be considered in HCA.
The friction cost approach (FCA) was developed to over-
come some unrealistic assumptions of the HCA, particu-
larly the assumption of perfectly competitive labour
markets, which implies existence of full employment (in
contrasttoempiricalexperienceofsubstantialunemploy-
mentinmanycountries)[15].FCAsuggeststhat,forlong-
term incapacity to work, costs of production loss are
limited to a so-called friction period – i.e. until a patient
will be replaced with a previously-unemployed individual
and the former production level will be restored (which
needs time for searching and training the previously-un-
employed). Costs in the FCA encompass production loss
in the friction period and transaction costs (searching
and training the previously-unemployed individual). For
short-term unfitness to work (within the friction period),
FCAarguesthatpartoftheworkloadmightbeperformed
by colleagues of the patient or made up by the patient
after return to work. Thus, short-term production losses
might be less than labour costs (according to HCA). Em-
pirical studies in the Netherlands found that short-term
costs are about 80 percent of labour costs [16]. Thus,
the cost difference between HCA and FCA may be small
for short-term absence from work while it will increase
markedly for long-term absence from work as HCA con-
siders all future productivity losses, while FCA is limited
to the friction period.
There is an ongoing debate in the literature whether HCA
or FCA is better representing productivity costs. As men-
tionedabove,thehumancapitalapproachrestsonsome
unrealistic assumptions (particularly full employment in
the labour market). HCA rather shows potential then real
production losses. In contrast, FCA is focused on real
productionlosses.Nevertheless,FCAhasbeencriticised,
too. In particular, the assumption of zero opportunity
costs of labour after the friction period has implications
on the calculation of direct medical costs. Then, it is ar-
gued, opportunity costs of labour inputs in health care
are nearly zero, too (because health care workers could
be substituted by a previously-unemployed individual at
nearly zero cost – only transaction costs for searching
and training the previously-unemployed individual would
accrue). In conclusion, it might be argued that HCA is
overestimating and FCA is underestimating opportunity
costs of paid work. Thus, according to international
guidelines sensitivity analyses are recommended [5].
3.6 Quality of life and quality-adjusted
life years
Health-related quality of life (HRQL) is an increasingly
important outcome parameter in health economic evalu-
ation. In the concept of health-related quality of life, the
general concept of quality of life (QoL) (including wealth,
liberty, education, culture and religion, amongst others)
is limited to health relevant dimensions. The definition
of health-related quality of life is derived from the WHO-
definition of health [17] – and comprises
• physical health
• mental health or emotional wellbeing
• social integration.
Approaches for measuring HRQL can be grouped into in-
dication specific measures, generic profile measures
(e.g., SF-36), and preference-based measures (e.g., EQ-
5D) [5]. Preference-based approaches provide a quality
of life index (i.e. a score reflecting HRQL numerically).
Like generic profile measures they can be used for com-
parisonsacrossindications.Preference-basedapproaches
are less differentiated and less sensitive than generic
profile measures (and even less sensitive than specific
measures).But–providingaQoL-index–thepreference-
basedmeasuresallowuniquecomparisonsofintervention
alternatives and thus are the only suitable approach for
cost-utility analyses.
The concept of quality-adjusted life years (QALYs) inte-
grates health-related quality of life and (remaining) life
expectancy into a one-dimensional outcome parameter
[18], [19]. The QALY approach is focused on the subject-
ive health of patients. With quality of life and life expect-
ancy the most relevant dimensions of health (from the
perspective of the individual) are considered.
The QALY approach allows comparisons across different
indications – in particular comparisons of life prolonging
interventions with mere QoL improving interventions (i.e.
not life prolonging interventions). HRQL scores are
measured on a cardinal scale ranging from 0 (death) to
1(completehealth).AQALYdenotesnumericallyoneyear
in complete health – or for example two years in a health
state valued 0.5. The QALY measure corresponds to the
integral of the QoL-function (over time) or – graphical –
the area under the QoL-index curve (in Figure 1). In a
discrete approach (with time as discrete parameter)
QALYs are the product of QoL of a health state and the
period the health state is realised.
3.7 Time horizon of the analysis
The time frame should be long enough to capture all
relevant cost and outcome differences between the pro-
grammescomparedinthehealtheconomicanalysis.For
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chronic conditions, a time horizon spanning to a lifetime
oftenisrequired(particularlyiflifespangainsareexpect-
ed).
Often,theappropriatetimehorizonexceedstheavailable
primarydata(fromprospectiveclinicalstudies),because
prospective studies mostly examine intermediate out-
comes(e.g.,reductionofbloodpressureorimprovement
of lung function capacity). Then it is appropriate to use
several time horizons in economic evaluations: a short-
termanalysisthatisbasedonlyondatafromprospective
studies (e.g., detected cases in a mammography
screening programme) and a long-term analysis that in-
cludes modelling data – based on epidemiologic studies
(e.g., effect of a sooner treatment on mortality, quality of
life und health care costs).
3.8 Discounting
There is a broad consensus in the literature, that costs
(and outcomes) should be discounted to their present
value to adjust for differential timing [20]. Discounting
reflects the positive time preference of individuals, i.e.
individuals prefer present to future benefits (as it leaves
more options). Reasons for a positive time preference
are (1) diminishing marginal utility of consumption, com-
binedwithexpectedincreasingfutureincomes(assuming
positiveeconomicgrowth)and(2)riskoflifespan,i.e.risk
whether future consumptions will be available. As is
shown in neoclassical theory, assuming perfect markets
with certain information about future (i.e. no risk) and
absence of taxation, the time preference will equal the
market interest rate (i.e. the opportunity cost of capital)
– indicating the social discount rate. Individuals will only
forgopresentconsumption,iffutureconsumption(based
on investment) is exceeding present consumption.
Usual discount rates range from 0 to 10 percent, often
rates of 5 or 3 percent are suggested in international
guidelines(forboth,costsandoutcomes).Thediscussion
of the so-called Keeler-Cretin paradox [20] resulted in
the recommendation of health economic guidelines to
discount costs and effects at an identical discount rate
[5].
3.9 Efficacy versus community
effectiveness
Randomisedcontrolledtrials(RCTs)formthemostappro-
priate study design to identify effects of an intervention.
Thus,Randomisedcontrolledtrialsformtheanalyticgold
standard in health economic evaluation studies – like in
clinicalstudies.Though,healtheconomicanalysisisless
interestedinefficacy(i.e.effectsunderstrictlycontrolled
study conditions), but more in community effectiveness
(i.e. effects under everyday life conditions)of health care
services. RCTs often are characterised by specific limita-
tions. Patients are included into the study by restrictive
inclusion and/or exclusion criteria (e.g., having no other
diseases). Furthermore, the clinical personnel are highly
motivated and the patients are particularly compliant.
Evaluation of community effectiveness will often not be
basedon RCTs, but on observationalstudieswith control
groups (where the allocation of patients to intervention
or control group is not randomised but depends on de-
cisions of physicians and/or patients). Using appropriate
multivariate statistics, ex-post comparableness of inter-
vention and control group is supported. Often the out-
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tions using epidemiologic models.
3.10 Analysis of uncertainty
In empirical evaluation studies the determination of cost
and outcome parameters is based on uncertain data
bases. Uncertainty rests on [5], [21]
• samplevariationsofpatient-baseddatainprospective
studies
• point estimates of prices for health care services and
resource use. Point estimates are based on data of
healthcareproviders,healthinsurancesand/orexpert
opinion
• extrapolation of intermediate outcomes to final out-
comes (e.g., blood pressure to life expectancy) in de-
cision models.
Healtheconomicevaluationstudiesshouldreportuncer-
tainty of cost and outcome parameters. Methods for
controlling parameter uncertainty due to sampling vari-
ations in prospective studies are statistical methods of
hypothesis testing and bootstrapping [6]. The effects of
otheruncertainassumptions–priceestimatesofservices
and resources and extrapolations – are examined in
(deterministic and stochastic) sensitivity analyses, i.e.
variations of parameters which are particularly relevant
for the study results.
4 Health economic evaluation of
newborn hearing screening
Inthissectionthemethodicalprocessofhealtheconomic
evaluation is illustrated using the example of newborn
hearingscreening.Specificrequirementsintheempirical
analysis of screening programmes are discussed.
4.1Screeningforcongenitalhearingloss
Theprevalenceofmoderatetoprofoundbilateralcongeni-
tal hearing loss is about 1 to 3 per 1,000 newborns [22].
When mild hearing impairment is included, prevalence
is about 5 to 6 per 1,000 newborns [23], [24]. 1 to 3 per
100 newborns is affected in the subgroup of high-risk
children [25], [26].
On average, congenital hearing impairment is diagnosed
attheageof31months(ifnonewbornhearingscreening
exists) [27], and initial provision of hearing aids takes
four more months. Moderate hearing impairment is
identified at the age of 46 months and mild hearing
impairment at the age of 48 months [27], [28], [29].
Delayedidentificationofhearingimpairmentimpliesthat
acrucialperiod(rangingfrom6to30monthsofage[30])
for language acquisition and verbal communication abil-
ities is missed – a period when neuronal structures for
languageacquisition(whicharehigh-sensitivetoauditory
stimuli) are developed [31], [13]). Hearing impairment
results in deficits in language acquisition and verbal
communication competence. Delayed identification also
produces subsequent impairments of cognitive, intellec-
tual, emotional und psychosocial development. Further-
more, access to education and vocation is more difficult.
Thus, it is required that infant hearing loss is identified
and treated in due time. Most experts agree that hearing
impairment should be identified before the age of 3
months and appropriate interventions (hearing aid or
cochlear implant, early language promotion) should be
initiated before the age of 6 months. Newborn hearing
screening is a detection strategy to identify hearing
impairment in due time. Two alternative tests methods
for newborn hearing screening exist: otoacoustic emis-
sions (OAE) and auditory brainstem response (ABR).
4.2 Questions
Thefollowingquestionsareaddressedbyhealtheconom-
ic analyses of newborn hearing screening
1. Howhigharethecostsofnewbornhearingscreening?
2. Isnewbornhearingscreeningcost-effectivecompared
to non-screening (i.e. usual treatment in a later –
symptomatic – phase of a target disease)?
3. Is a universal hearing screening cost-effective com-
pared to selective hearing screening for high-risk in-
fants?
4. Which institutional access for universal newborn
hearing screening is more cost-effective – hospitals
or paediatric practices?
5. Whichaccessisreachingmorechildrenforscreening?
6. Whichlong-termoutcomesarerealisedby(universal)
newborn hearing screening?
These questions are discussed in the following sections.
4.3 Methods
Nine health economic studies of newborn hearing
screening (since 1998) were identified ([22], [16] and
own literature search). Most studies restricted their an-
alysis to screening test and confirmation. Only one study
[32] described long-term costs and outcomes.
4.4 Costs of newborn hearing screening
There are several studies calculating costs of newborn
hearing screening [32], [33], [34], [35], [36], [37], [38],
[39].InGermanyonecost-analysiswasconductedunder
everyday life conditions (the so-called Hannover Model
Project) [40].
The Hannover Model Project evaluated the introduction
of a universal hearing screening in the Hannover region.
Screening was executed in all maternity clinics (well ba-
bies) and neonatal intensive care units (NICU) (high-risk
infants) of the Hannover region. For ambulant births and
homebirthsscreeningwasdelegatedtoalimitednumber
ofoffice-basedotorhinolaryngologists.Thescreeningtest
method applied was OAE. Between 07/2000 and
8/14 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2008, Vol. 7, ISSN 1865-1011
Krauth: Health economic analysis of screening12/200217,920newbornswerescreenedbythehearing
screening programme.
In the Hannover Model Project a micro-costing approach
wasappliedforcalculatingscreeningcosts.Thefollowing
programme components were included
• programme development
• programme implementation
• monitoring
• initial OAE-measurement in clinics
• confirmation of test-positive results (in selected
otorhinolaryngologist’s practices).
The micro-costing approach is based on quantification
and valuation of resource use – personnel, materials,
equipment, building and overheads [41]. Labour utilisa-
tion formed a dominant part of screening costs. Thus,
labour utilisation in the screening programme was pre-
cisely calculated, using time records, oral interviews and
documentations.Valuationoflabourutilisationwasbased
on employers’ labour costs.
Programmeimplementationincludedinformation,instruc-
tions (how to administer the screening test), motivation
ofandassistancetohospitalsandparticipatingpractices
during the introduction of the screening programme in
the Hannover region. The monitoring process aimed at
giving prompt feedbacks to hospitals on their screening
rates (i.e., screened children as percentage of all births
in a clinic). For both, implementation and monitoring, re-
source use (particularly personnel) of the screening co-
ordination unit (located at the Hannover Model Project),
and of clinics and practices was quantified.
OAE-devices (depreciation and interest) and personnel
(information of parents, measurement, documentation
of measurement results, and organisation of the initial
screening test) were the dominant cost components of
the initial screening test for hearing loss conducted in
clinics.TimeexpenditureforcompleteOAE-measurement
per child (including repetitions if necessary) was about
10 minutes, and costs of measurement per child were
about 10 euro. Confirmation of test-positive screening
results was conducted by certificated otorhinolaryngolo-
gist’s practices. Costs of confirmation were estimated to
23.1 euro per false-positive case and 80 euro per true-
positive case (due to larger expenditures as the total
processofconfirmationmustbeapplied).Screeningcosts
(for programme development and implementation,
monitoringandinitialOAE-measurement,butnotconfirm-
ation) amounted to about 23 euro per child screened
(see Table 3).
AstheHannoverModelProjectevaluatedtheintroduction
of a newborn hearing screening programme, substantial
experience-based cost savings are expected (e.g., for in-
struction, assistance and monitoring of clinics and prac-
tices) when the screening programme is run longer. For
example,inindustrialproductionexperiencecurveeffects
areverifiedbyempiricalstudies.Averagecostreductions
are estimated to about 20% of unit production costs if
cumulated output is doubled [42]. Furthermore, costs
per child screened for programme development and im-
plementation is decreasing the longer the screening
programme is existing (i.e., the more newborns are
screened) as implementation costs only accrue during
the introduction period. In the present calculation imple-
mentation costs are about 36% of total screening costs.
Thus, substantial reductions of screening costs are ex-
pected in the long run. A model analysis calculated long-
termcostsofabout16europerchildscreened(including
confirmationcosts).Theaveragecostspercaseidentified
are about 15,500 euro.
In international studies screening costs range from 14
to 25 euro per child screened [32], [33], [34], [36], and
costs per case detected range from 5,000 to 31,000
euro[32],[34],[36],[39].Thus,Germanscreeningcosts
are in the range of international screening costs.
4.5 Cost-effectiveness analysis of
newborn hearing screening –
comparison of universal screening,
screening of high-risk children, and
non-screening
Averagecostsperidentifiedcase(aspresentedinsection
4.3) are not relevant to health economic decisions. De-
cisionsareratherbasedoncomparativehealtheconomic
evaluations calculating cost and outcome (e.g., health
effect or quality-adjusted life year) differences between
two or more relevant intervention alternatives. Thus, in
thepresentanalysesincrementalcostsandoutcomesof
a screening programme (compared to intervention alter-
natives) are determined. The incremental cost-effective-
ness ratio of a screening programme describes the addi-
tional costs per additional case identified (compared to
relevant intervention alternatives).
Only one study (of nine health economic studies of new-
bornhearingscreeningidentifiedinasystematicliterature
search (see section 4.3)) is performing a comparison of
screening to non-screening [32]. Keren et al. compare
(1) a universal newborn hearing screening, (2) newborn
hearing screening of high-risk children, and (3) non-
screening.Evenifnoscreeningprogrammeisimplement-
ed some cases are identified in due time – particularly
children with profound hearing loss. Then, costs of iden-
tification and confirmation must be considered.
In the model analysis by Keren et al., 116 cases (of 128
expected cases from a birth cohort of 80,000 children)
areidentifiedduringthefirstsixmonthsofageifauniver-
sal hearing screening is implemented, 62 cases if
screening is restricted to high-risk newborns, and still 30
cases if no screening is implemented. The average costs
per identified case amount to 2,300 euro for non-
screening, 10,100 euro for screening high-risk children,
and 21,700 euro for universal screening.
Keren et al. calculate incremental cost-effectiveness ra-
tios for screening high-risk infants compared to non-
screening and (2) for universal screening compared to
screeninghigh-riskinfants.(1)Incrementalcostsamount
to 16,600 euro per additional identified case for screen-
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ing high-risk newborns compared to non-screening (de-
tecting 32 additional cases in the first six months of age)
and (2) to 45,000 euro per additional identified case for
universal screening compared to screening high-risk
children (detecting 54 additional cases).
The analysis demonstrates that incremental costs in-
crease compared to average costs (45,000 euro versus
21,700 euro for universal hearing screeningand 16,600
euroversus10,100euroforscreeninghigh-riskchildren).
4.6 Analysis of participant rates and
costs of different institutional access to
newborn hearing screening
Based on the empirical results of the Hannover Model
Project (see section 4.4) model analyses of newborn
hearingscreeningforGermany(in2001)wereperformed.
Alternative institutional access – screening in hospitals
(model1)versusscreeninginpaediatricpractices(model
2) – were compared regarding participation rates and
programme costs. A similar comparison of hospital and
ambulantscreeningwasmodelledfortheUKhealthcare
system [43].
Model 1 (“inpatient newborn hearing
screening”)
In model 1 newborn hearing screening is performed in
maternityclinics(wellbabies)andneonatalintensivecare
units (high-risk infants). For ambulant and home births
screening was delegated to a limited number of office-
basedotorhinolaryngologists.Thisinstitutionalscreening
structure of model 1 corresponds to the screening pro-
gramme of Hannover Model Project.
Model 2 (“ambulant newborn hearing
screening”)
In model 2 newborn hearing screening is performed in
paediatric practices during routine well child visits (so-
called U3 at 4 to 6 weeks of age) and neonatal intensive
care units (high-risk infants).
Theassumptionsofthemodelanalysesaresummarised
in Table 4. Prevalence rates, validity (sensitivity and
specificity), distribution of children to the screening insti-
tutions (maternity clinics, neonatal intensive care units,
practices) in model 1, and screening rates of these
screening institutions (i.e. screened children as percent-
age of all births in an institution) are based on the empir-
ical results of the Hannover Model Project.
Models 1 and 2 differ in screening rates and specificity
ofthescreeningtest.TheHannoverModelProjectshowed
differences in test specificity between clinics and prac-
tices (about 90% in clinics and 80% in practices). The
lower specificity is due to worse screening conditions in
practices (e.g., narrow time period for screening). How-
ever, the estimated screening rate is much higher in
paediatric practices of model 2 (98%) than in maternity
clinics of model 1 (93.5%). The assumed screening rate
in paediatric practices corresponds to the nationwide
participation rate of U3 routine well child visits. The
screening rate in maternity clinics is lower because a
substantialpart of newborns leaves hospital before valid
test results can be produced (i.e. before 2 to 3 days after
birth).
In model 1 (inpatient newborn hearing screening) about
50,000newborns(of735,000birthsperyearinGermany)
missscreening.710hardofhearingchildrenaredetected
and 93 hearing-impaired newborns are not identified by
the inpatient screening programme. About 73,000 false-
positive cases must undergo confirmation diagnostics.
In model 2 (ambulant newborn hearing screening) about
16,000 children are not screened. 741 hearing-impaired
newborns are detected and 62 hard of hearing children
arenotidentifiedbytheambulantscreeningprogramme.
About 136,000 false-positive cases must undergo con-
firmation diagnostics. Thus, ambulant screening (model
2) identifies 31 more hearing-impaired newborns than
inpatient screening (model 1). However, significantly (i.e.
about 63,000) more test-positive children than in model
1 need confirmation diagnostics. Cost differences
between models 1 and 2 are due to
• higher investments in OAE-devices and higher time
expenditures for monitoring in model 2 (ambulant
screening)astherearemuchmorepaediatricpractices
than maternity clinics
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• higher expenditures for confirmation diagnostics in
model 2 (ambulant screening) as significantly more
false-positive test results are produced
• larger number of screened infants in model 2 (ambu-
lant screening).
Inmodel1(inpatientscreening)totalscreeningcosts(for
implementation, monitoring, initial measurement, and
confirmation) are estimated to 11 million euro if the
screening programme is extended to Germany. The aver-
age costs per screened newborn are 16.1 euro (with
about685,000screenedchildren),andaveragescreening
costs per case identified amount to 15,500 euro (with
710 hearing-impaired children detected).
In model 2 (ambulant screening) total screening costs
are estimated to 24.2 million for Germany. The average
costs per screened newborn are 33.8 euro (with about
718,000screenedchildren),andaveragescreeningcosts
per case detected amount to 32,700 euro (with 741
hearing-impaired newborns identified).
Thus, programme costs of ambulant screening model 2
are about 13.2 million euro more expensive than pro-
gramme costs of inpatient model 1. However, ambulant
screening model 2 identifies 31 more hearing-impaired
newborns than inpatient screening model 1. The incre-
mentalcost-effectivenessratio–i.e.additionalcostsper
additional case identified of ambulant screening com-
pared to inpatient screening – is 426,000 euro (13.2
millioneuro/31cases).Whethermodel2iscost-effective
must be decided by decision makers (e.g., Federal Joint
CommitteeforGermany).Long-termoutcomesshouldbe
considered when a decision is made on the nationwide
introduction of newborn hearing screening.
4.7 Long-term outcomes of newborn
hearing screening
Most health economic studies of newborn hearing
screening analyse costs per identified case which is an
indicator for short-term cost-effectiveness. However, the
time frame should be long enough to capture all relevant
cost and outcome differences between intervention al-
ternatives compared in health economic analyses. To
evaluate interventions for hearing-impaired children, a
time horizon spanning to a lifetime is required. The cost
calculation includes
• health care costs
• cost of education and
• loss of human capital (due to lower education).
Thesmallnumberoflong-termhealtheconomicanalyses
is due the small number of long-term effectiveness
studies analysing screening and/or early interventions
(e.g., hearing aid or cochlear implant).
Only two studies (of nine health economic studies of
newborn hearing screening identified in a systematic lit-
erature search (see section 4.3)) evaluate the long-term
effects of newborn hearing screening [44], [45]. More
studies examine how long-term outcomes depend on
detection age of hearing loss and/or intervention age
(e.g., hearing aid or cochlear implant, early language
promotion) [46], [47], [48], [49], [50], [51], [52], [53],
[54], [55]. The following long-term outcome parameters
are considered
• language acquisition
• cognitive development
• pre-school and school performance (education costs)
• professional career (human capital)
• quality of life.
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development [44], [45], [46], [47], [48], [49], [50], [51],
[52], but only few studies analyse school performance
and professional career [53], [54], [55] as long-term ob-
servationsofatleast6and16yearsarerequired,respect-
ively. Furthermore, most evaluations focus on cochlear
implant supply for children with profound hearing loss
[48],[49],[50],[51],[52].Thoughmostgainintime(and
benefit) of newborn hearing screening is expected for in-
fants with moderate hearing loss.
The studies’ results on long-term outcomes can be sum-
marised as follows: Universal hearing screening shows
significantlypositiveeffectsonreceptivelanguagedevel-
opment of hearing-impaired children [44], [45], but only
non-significant (positive) effects on expressive language
development [45]. Similar results are found for earlier
compared to later diagnosis and intervention [46].
In the subgroup of children with profound hearing loss,
cochlear implants show better effects on general lan-
guagedevelopmentthanhearingaids.Thisisparticularly
true if the cochlear implant is supplied before the age of
4 years [56]. Language acquisition is the better the
soonercochlearimplantsaresupplied[50],[52].Studies
of schoolperformanceand professionalcareerexist only
for deaf children. Again, children with earlier cochlear
implantation are more likely to visit regular kindergarten
and regular schools, respectively [53], [54].
In most studies confounding parameters (like education
and income of parents, and family support) are not con-
trolled. Thus, the existing studies of long-term outcomes
are insufficient to prove long-term cost-effectiveness of
newborn hearing screening.
5 Discussion and conclusion
This article examined health economic implications of
screening. Requirements screening programmes should
fulfil were developed. Main requirements for the imple-
mentation of screening programmes are
• the target disease should be a substantial health
problem
• an effective treatment should be available. Treatment
outcomes should be the better the earlier the disease
is detected
• the disease should be diagnosable in a latent or pre-
symptomatic phase
• a simple, safe and sufficiently precise screening test
should exist to detect the target disease
• anadequateinfrastructureforscreening,diagnostics,
and treatment should exist.
Requirements the evaluation of screening programmes
should fulfil are as follows
• systematicerrorsshouldbeavoided.Intheevaluation
of screening tests lead time bias and length time bias
are particularly relevant. The effects of these two
biases should be controlled by randomised controlled
trials
• the time frame of a health economic analysis should
be long enough to capture all relevant cost and out-
come differences between the intervention alternat-
ives.Often,long-termeffectsarepresentedindecision
models
• health economic evaluations are based on a compari-
son of relevant intervention alternatives (e.g., screen-
ing versus non-screening). The main health economic
criterion is the incremental cost-effectiveness ratio
(e.g., additional costs per additional case identified).
An application of these requirements to the example of
newborn hearing screening shows the following results
• healtheconomicstudiesofnewbornhearingscreening
are not randomised, most studies are even not con-
trolled
• thus, most studies do not present incremental costs
per additional case identified by newborn hearing
screening(compared to non-screening),but only aver-
age costs per identified case
• moststudiesfocusonshort-termoutcomesofnewborn
hearing screening (i.e. identified cases). Only one
model analysis examines long-term outcomes
• the evidence on long-term outcomes is not sufficient
to develop health economic decision models.
Obviously, the empirical studies of newborn hearing
screeningdo not meet allrequirementshealtheconomic
evaluation of screening should meet. However, empirical
studies cannot fulfil all requirements. Particularly, a ran-
domised-controlled trial of universal newborn hearing
screening is not feasible. It would need about 100 study
regions with each 1 million inhabitants to find significant
outcome differences. Recruitment of control regions for
a controlled trial is difficult as control regions are not
motivatedtoparticipateinthetrial.Furthermore,atleast
unsystematic hearing screening is provided in most re-
gions. Thus, an improvement of outcomes (e.g., an in-
creaseinidentifiedcases)ofscreeningcomparedtonon-
screening cannot be proved. Nevertheless, there is a
need for controlled trials (to examine differences in
identified cases, but particularly to examine long-term
effects).
In the end, (short-term) outcomes of a screening pro-
gramme depend on programme infrastructure, process
managementincludingestablishedcontrolroutines,and
capacities for screening and confirmation diagnostics.
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